Across TCGA pan-cancer cohorts, ANO9 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ANO9 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ANO9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANO9 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

HNSC and PDAC are the cancer types where ANO9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.217	0.747	.025	8	view →
PDAC	OS	Median	All	0.996	0.810	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: ANO9 tumor-vs-normal RNA expression · all ANO9 data types